December 2016
-
By Jason A Suggett, Mark W Nagel, Dominic P Coppolo, and Jolyon P Mitchell A wide spectrum of options is available for delivering inhaled medications by nebulization. The challenge, either for a developer considering which… Read more . . .
-
DPI developer Iconovo has announced that the Japanese Patent Office has granted the company a patent covering its ICOres dry powder inhaler. According to Iconovo, Sweden and European patents related to ICOres have already been… Read more . . .
-
Iliad Biotechnology has announced the appointment of Cheryl Keech as Chief Medical Officer and Executive VP of Clinical Research; she will be responsible for clinical studies of the company’s pipeline products, including the BPZE1 live… Read more . . .
-
Hovione Technology said that the company has completed pilot-scale blister manufacturing and filling for its Papillon dry powder inhaler. The company announced in April 2019 that it had acquired the rights to the DPI from… Read more . . .
-
Swedish CDMO Recipharm has announced that it will acquire Consort Medical, the parent company of device maker Bespak and CDMO Aesica, in order to “Become a Leading Inhalation Company and Top Five Global CDMO Player.”… Read more . . .
-
Levo Therapeutics has announced that the FDA has granted Fast Track designation to its LV-101 intranasal carbetocin for the treatment of Prader-Willi syndrome (PWS). In December 2018, Levo said that it was initiating the CARE-PWS… Read more . . .
-
According to Seelos Therapeutics, the FDA has granted Fast Track designation to its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder. The company also… Read more . . .
-
Savara has announced the appointment of Badrul Chowdhury, as Chief Medical Officer, a newly created position. From 2002-2018, Chowdhury was the Director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and… Read more . . .
-
French drug delivery device company Biocorp announced that it has entered into a 10-year strategic partnership with Vitrobio Pharma regarding manufacturing of a new intranasal polymeric product that the company says “acts as a barrier… Read more . . .
-
On November 1, 2019, Aquestive Therapeutics filed a citizen petition asking the FDA to stay approval of a 505(b)(2) NDA submitted by Neurelis in September 2018 for Valtoco diazepam nasal spray for the treatment of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK